Geographic Area
Gilead’s Kite Unit Exits China CAR-T Joint Venture with Fosun
Gilead Sciences, Kite Pharma, Fosun Pharma, CAR-T cell therapy, joint venture, China, Yescarta
Gilead’s Kite Terminates China Cell Therapy Joint Venture with Fosun Pharma
Gilead Sciences, Kite Pharma, Fosun Pharma, cell therapy, joint venture, China, CAR-T therapy, Yescarta
IO Biotech’s IO102-IO103 Vaccine in Combination with Keytruda Shows Promising Results in Phase 2 Trial for Advanced Squamous Cell Carcinoma of the Head and Neck
IO Biotech, IO102-IO103, Keytruda (pembrolizumab), Phase 2 trial, Squamous cell carcinoma of the head and neck (SCCHN), Cancer vaccine, Immunotherapy
ESMO 2024: IO Biotech’s IO102-IO103 Vaccine in Combination with Pembrolizumab Shows Promising Results in Head and Neck Cancer
IO Biotech, IO102-IO103, Pembrolizumab (Keytruda), Head and Neck Cancer, ESMO Congress 2024, Therapeutic Cancer Vaccine, Immunotherapy
Biotech IPO Market Sees Rare Upsurge with Triple Listing Success
Biotech IPO, Market Flux, Tripleheader, Bicara Therapeutics, Zenas BioPharma, MBX Biosciences, Stock Surge, Pharmaceutical Industry
Sanofi’s $1 Billion Bet on Muscular Dystrophy Drug Falters, Fulcrum Shares Plummet
Sanofi, Fulcrum, muscular dystrophy drug, pharmaceutical failure, stock market impact
Eli Lilly Expands Irish Manufacturing with Additional $1B Investment
Eli Lilly, Ireland, manufacturing expansion, biologics, pharmaceuticals, investment, Limerick, Kinsale
BIOSECURE Act Clears House Hurdle, Heads to Senate for Vote on Restricting Chinese Biotech Ties
BIOSECURE Act, House of Representatives, Senate Vote, Chinese Biotech Companies, National Security Risks, U.S. Pharmaceutical Industry, Biotechnology Innovation, Drug Supply Chain
Milestone’s Etripamil Nasal Spray Advances Towards Regulatory Filing in China for PSVT Treatment
Etripamil nasal spray, Paroxysmal supraventricular tachycardia (PSVT), Milestone Pharmaceuticals, Ji Xing Pharmaceuticals Ltd, China regulatory filing, Cardiovascular therapies
Connect Biotech Scales Back in China, Reassesses Strategy for Asthma Drug to Compete with Dupixent
Connect Biotech, China workforce reduction, Dupixent rival, asthma drug strategy, biotech industry